BMT Tandem "Scientific" Meeting
Seaport Ballroom ABC (Manchester Grand Hyatt)
Joseph DePalo
,
Harvard School of Dental Medicine, Boston, MA
Xiaoyu Chai, MS
,
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Stephanie J. Lee, MD, MPH
,
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Corey S. Cutler, MD
,
Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Chronic GVHD (cGVHD) is a frequent
complication of allogeneic hematopoietic stem cell transplantation (HSCT) and
affects multiple organ systems, with the oral cavity being one of the most
frequently affected sites. Patients with cGVHD experience reduced quality of
life (QOL), yet the specific impact of oral cGVHD on QOL is poorly understood. The
objective of this study was to characterize the impact of oral cGVHD on global
measures of QOL. METHODS: QOL data were collected using the FACT-BMT
and SF-36 instruments for 569 patients enrolled in the Chronic GVHD Consortium,
with a total of 1,915 follow-up visits. At study enrollment, patients were
categorized as isolated oral cGVHD (n=22), oral and concomitant extra-oral
cGVHD (n=420), and only extra-oral cGVHD (n=127). Utilizing all longitudinal
data, QOL scores were compared using a multivariable linear model controlling
for demographic, transplant, and cGVHD characteristics. RESULTS: Patients with isolated oral cGVHD reported
better physical well-being (P=0.009), BMT well-being (P=0.01), and decreased
bodily pain (P=0.01) compared to patients with oral and concomitant extra-oral
cGVHD. A similar trend was observed that patients with isolated oral cGVHD
reported better physical well-being (P=0.02) and less bodily pain (P=0.02)
compared to patients with only extra-oral cGVHD. QOL scores were
similar in several domains, most notably social/family well-being, physical
role functioning, and vitality, when comparing patients with isolated oral cGVHD
to patients with oral and concomitant extra-oral cGVHD and only extra-oral cGVHD.
CONCLUSIONS: Isolated oral cGVHD is associated with better QOL compared
to extra-oral cGVHD across multiple domains, in particular physical well-being
and bodily pain.
Multivariable
analysis comparing quality of life scores
| | Isolated oral vs. oral and extra-oral | Isolated oral vs. only extra-oral |
| | difference in QOL scores between groups | p-value | difference in QOL scores between groups | p-value |
FACT-BMT | | | | | |
| total | 3.14 | 0.03 | 1.58 | 0.32 |
| physical well-being | 1.09 | 0.009 | 1.09 | 0.02 |
| social/family well-being | 0.17 | 0.63 | -0.13 | 0.75 |
| emotional well-being | 0.45 | 0.14 | 0.07 | 0.85 |
| functional well-being | 0.88 | 0.05 | 0.29 | 0.56 |
| BMT well-being | 1.10 | 0.01 | 0.81 | 0.10 |
SF-36 | | | | | |
| PCS | 1.20 | 0.14 | 1.08 | 0.23 |
| MCS | 0.17 | 0.85 | -0.67 | 0.50 |
| physical functioning | 0.96 | 0.25 | 0.79 | 0.39 |
| physical role functioning | -0.29 | 0.76 | -0.52 | 0.62 |
| bodily pain | 2.26 | 0.01 | 2.43 | 0.02 |
| general health perceptions | 1.62 | 0.05 | 0.22 | 0.81 |
| vitality | 0.07 | 0.94 | -0.50 | 0.60 |
| social role functioning | 1.29 | 0.21 | 0.81 | 0.47 |
| emotional role functioning | 0.46 | 0.67 | -0.72 | 0.54 |
| mental health | 0.27 | 0.75 | -0.43 | 0.64 |
BMT= bone marrow transplant.
PCS= physical component score. MCS= mental component score.
Disclosures:
Nothing To Disclose